IGM Biosciences, Inc. (IGMS)
NASDAQ: IGMS · Real-Time Price · USD
15.47
-0.22 (-1.40%)
Nov 5, 2024, 11:13 AM EST - Market open

Company Description

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases.

It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.

IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies.

The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010.

IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

IGM Biosciences, Inc.
IGM Biosciences logo
Country United States
Founded 1993
IPO Date Sep 18, 2019
Industry Biotechnology
Sector Healthcare
Employees 224
CEO Mary Harler

Contact Details

Address:
325 East Middlefield Road
Mountain View, California 94043
United States
Phone 650 965 7873
Website igmbio.com

Stock Details

Ticker Symbol IGMS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001496323
CUSIP Number 449585108
ISIN Number US4495851085
Employer ID 77-0349194
SIC Code 2834

Key Executives

Name Position
Mary Beth Harler M.D. Chief Executive Officer and Director
Dr. Bruce A. Keyt Ph.D. Chief Scientific Officer
Dr. Chris H. Takimoto FACP, M.D., Ph.D. Chief Medical Officer
Misbah Tahir Chief Financial Officer
TS Harigopal Senior Vice President of Group Operations
Steven Weber Senior Vice President, Corporate Controller and Principal Accounting Officer
Paul C. Graffagnino Senior Vice President of Legal Affairs
Suzette Tauber Chief Human Resources Officer
Dr. Angus M. Sinclair Ph.D. Senior Vice President of Immuno-Oncology
Dr. Lisa L. Decker Ph.D. Chief Business Officer

Latest SEC Filings

Date Type Title
Oct 3, 2024 8-K Current Report
Aug 14, 2024 8-K Current Report
Aug 14, 2024 10-Q Quarterly Report
Aug 2, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jul 25, 2024 144 Filing
Jul 22, 2024 SC TO-I/A Filing
Jul 5, 2024 8-K Current Report
Jul 3, 2024 SC TO-I/A Filing
Jul 1, 2024 SC TO-I/A Filing
Jun 26, 2024 UPLOAD Filing